

## Product datasheet for **TL313206V**

### ENPP3 Human shRNA Lentiviral Particle (Locus ID 5169)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	ENPP3 Human shRNA Lentiviral Particle (Locus ID 5169)
Locus ID:	5169
Synonyms:	B10; CD203c; NPP3; PD-IBETA; PDNP3
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ENPP3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_005021</a> , <a href="#">NR_133007</a> , <a href="#">NM_005021.1</a> , <a href="#">NM_005021.2</a> , <a href="#">NM_005021.3</a> , <a href="#">NM_005021.4</a> , <a href="#">BC141434</a> , <a href="#">BC146579</a> , <a href="#">NM_005021.5</a>
UniProt ID:	<a href="#">O14638</a>
Summary:	The protein encoded by this gene belongs to a series of ectoenzymes that are involved in hydrolysis of extracellular nucleotides. These ectoenzymes possess ATPase and ATP pyrophosphatase activities and are type II transmembrane proteins. Expression of the related rat mRNA has been found in a subset of immature glial cells and in the alimentary tract. The corresponding rat protein has been detected in the pancreas, small intestine, colon, and liver. The human mRNA is expressed in glioma cells, prostate, and uterus. Expression of the human protein has been detected in uterus, basophils, and mast cells. Two transcript variants, one protein coding and the other non-protein coding, have been found for this gene. [provided by RefSeq, Oct 2015]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).